1. THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. (15th July 2016) Authors: Kavanaugh, A.; Gladman, D.D.; Edwards, C.J.; Poder, A.; Lioté, F.; Bird, P.; Schett, G.; Nguyen, D.; Teng, L.; Mease, P.J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0420 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. (15th July 2016) Authors: Mease, P.; Marzo-Ortega, H.; Poder, A.; Van den Bosch, F.; Wollenhaupt, J.; Lespessailles, E.; McIlraith, M.; Teng, L.; Hall, S. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 341 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2018 European guideline on the organization of a consultation for sexually transmitted infections. (10th April 2019) Authors: Gamoudi, D.; Flew, S.; Cusini, M.; Benardon, S.; Poder, A.; Radcliffe, K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 8(2019) Page Start: 1452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗